Hulskof schreef op 12 oktober 2021 18:29:
Recording the biggest intraday gain ever, Inhibrx (INBX +22.8%) has added more than a fifth of value for its market cap after disclosing interim Phase 1 data for INBRX-101 in alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder affecting lungs.
With results indicating the favorable safety profile of the drug with potential for monthly dosing, Evercore ISI has increased its price target to a Wall Street high of $60 from $50 per share. That implies a premium of ~117.3% to the last close.
The analyst Joshua Schimmer who maintains the outperform rating on the stock, argues that INBRX-101 demonstrated a good safety profile, and its pharmacokinetics outperformed what was seen in animal studies.
Among developers targeting AATD, Arrowhead Pharmaceuticals (ARWR +4.0%) is trading higher today, while Vertex Pharmaceuticals (NASDAQ:VRTX), which abandoned its plans to develop an AATD therapy in June, is trading flat.
Dat verklaart ws de stevige plus vandaag...